Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Inclusion Criteria: * Prostate cancer * Patient must have received primary definitive local therapy to the prostate (surgery and/or radiotherapy) * Patient was surgically or pharmacologically castrated at least 6 months prior to starting the study * Patient must have had a previous trial of anti-androgen therapy * Patient must have a rising PSA * No evidence of distant metastatic disease * ECOG performance status \< 2 * Age \>18 years * Patients must have normal hepatic function Exclusion Criteria: * Patients with a history of any previous cytotoxic therapy or radionuclide therapy (such as rhenium, strontium, or samarium) * Patients may not be receiving any other investigational agents * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients receiving renal dialysis * Patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization will be excluded * Patients who have known hypersensitivity to any of the AndroGel ingredients, including testosterone that is chemically synthesized from soy